Ginkgo Bioworks (DNA) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OmniAb (OABI) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 166.3% versus a loss of 29.5%. Over five years, OABI leads with a -53.3% price change compared with -97.6% for DNA. Ginkgo Bioworks is the larger company by market cap ($763.6 million vs $677.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | OABI |
|---|---|---|
| Share price | $11.34 | $4.66 |
| Market cap | $763.64M | $677.52M |
| 1-day change | -1.13% | +2.19% |
| YTD return | +36.46% | +151.89% |
| 1-year return | -29.52% | +166.29% |
| 5-year return | -97.62% | -53.26% |
| EPS (TTM) | $-5.06 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $5.43 |
| 52-week low | $5.37 | $1.30 |
| Distance from 52-week high | -37.76% | -14.18% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -38.27% | +78.76% |
| Average volume | 1.80M | 1.47M |
| Shares outstanding | 55.38M | 145.39M |
| Employees | 485 | 89 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed DNA by 195.8 percentage points over the past year.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Healthcare · Biotechnology · 485 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Healthcare · Biotechnology · 89 employees
DNA vs OABI FAQ
Which is bigger, Ginkgo Bioworks or OmniAb?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $763.64M compared with $677.52M for OmniAb (OABI).
Which stock has performed better over the past year, DNA or OABI?
OABI returned +166.29% over the past 12 months, compared with -29.52% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and OmniAb in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.